A crossover study of lecithin treatment of tardive dyskinesia.
The authors enrolled 21 patients in a random-order, crossover, double-blind trial of phosphatidylcholine (lecithin) 20 g/day and placebo. Fourteen patients completed at least 6 weeks of the second 8-week trial and were used for efficacy analyses. Side effects were minimal. The lecithin treatment effect--about one half of an Abnormal Involuntary Movement Scale point--was seen as a statistical effect of treatment order, based on differences between patients who took the active compound before or after they took the placebo. Clinically, however, the lecithin effect was negligible.
Gelenberg
A J
AJ
Department of Psychiatry, University of Arizona College of Medicine, Tucson 85724.
Dorer
D J
DJ
Wojcik
J D
JD
Falk
W E
WE
Brotman
A W
AW
Leahy
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D001294:Attitude to Health; D002794:Choline / Q000097:blood; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010808:Physical Examination; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic; D011795:Surveys and Questionnaires
D010713:Phosphatidylcholines; D010919:Placebos; D002794:Choline